Step 1 of 2
These slides cover the evolving role of GPRC5D-directed bispecific antibodies in relapsed/refractory multiple myeloma. Take a look at evidence supporting CAR T-cell therapies and bispecific antibodies across the treatment continuum and explore considerations for treatment selection and sequencing of GPRC5D-directed therapy in the current treatment landscape, emerging data for talquetamab-based strategies, and factors that may influence outcomes following prior targeted therapy. The activity also addresses practical approaches to GPRC5D-directed bispecific antibody dosing, toxicity prevention, management, and patient counseling to support safe and effective integration of talquetamab into clinical practice.